In the first part of the present study we compared the antigenicity of affinity-purified acetylcholine receptors from the cell line TE671 and from human skeletal muscle. The reactivities of the two acetylcholine receptor preparations showed a strong correlation (r = 0.96) in a radioimmunoassay using sera from myasthenia gravis patients. In additional functional studies, carbamylcholine stimulated cAMP production in TE671 cells to 130%. This increase was even more pronounced when TE671 cells were grown in the presence of dexamethasone. -Bungarotoxin completely blocked this carbamylcholine-induced cAMP increase. Using the Ca 2 + indicator, indo-1, it was shown that intracellular Ca 2+ concentrations ([Ca 2+ ]j) were elevated in TE671 cells after stimulation with carbamylcholine. This effect was also completely blocked by oc-bungarotoxin. To test the functional activity of autoantibodies against the acetylcholine receptor, TE671 cells were preincubated with sera from myasthenia gravis patients. In one third of sera a significant inhibition of the agoniststimulated [Ca 2+ ]i increase was detected, possibly caused by antibodies directed to functionally important areas of the acetylcholine receptor. There was no correlation between the inhibition rate of [Ca 2+ 
Introduction
. '· n /< o\ ? · · * --immunologically (1, 2) . For immunological studies in Autoantibodies direct against the human äcetylcho-myasthenia gravis these receptors are less useful beline receptor are known to play an important role in^ cause of their low cross-reactivity to human acetylthe pathogenesis of myasthenia gravis. However, iso^· choline receptor (3, 4) . Therefore, human acetylcholation of the target structure, the acetylcholine recep-' line receptor from amputated leg muscle tissue has tor from human muscle tissue, is difficult and various usually been applied as autoantigen in different aspreparations differ in their antigenicity. As an alter-says. However, the supply of human muscle is limited native we isolated the acetylcholine receptor from the and more importantly, during the preparation human human cell line TE671 and investigated its reaction muscle acetylcholine receptor is easily degraded (5, with human autoantibodies immunologically and 6). The human TE671 cell line expresses significant functionally.
numbers of acetylcholine receptors and is therefore a r™ . . . , t i-· . · " .,-, useful alternative source for acetylcholine receptor The nicotimc acetylcholine receptor, initially purified ,. ^,. " ,. . ... " , ., , -
J f ·%.,.,, preparations. This cell line was initially described as irom electric organs of certain fish species has been , , " ,, . ,. , ,, A11 . 0 ~ , « , . , ,. , . " ' , · t, a human medulloblastoma line by McAllister & Gardcharacterized biochemically, pharmacologically and /aN T . , ., . . , . , , tor subunits from TE671 cells, which show a complete homology to nucleotide sequences described for human skeletal muscle type acetylcholine receptor subunits (9) .
In the present study we demonstrated a cross-activity of myasthenia gravis patient sera with acetylcholine receptor preparations from human muscle and from TE671 cells.
Furthermore, TE671 and the neuroblastoma line IMR32 (10) , both of which express a-bungarotoxin binding sites, were tested to determine whether these α-bungarotoxin binding proteins represent functional acetylcholine receptors. This was done by measuring intracellular signal transduction, i. e. the increase in cAMP and the increase in intracellular Ca 2+ concentration after stimulating cells with the acetylcholine receptor-specific agonist carbamylcholine. Finally, both cell lines were used to test whether autoantibodies from myasthenia gravis patient sera (n = 11) modulate acetylcholine receptor-induced signal transduction.
Materials and Methods
Cell culture IMR32 (CCL 127) and TE671 (HTB 139) cells were obtained from the American Tissue Culture Cooperation (ATCC). Both lines were grown in Dulbecco's modified Eagle's medium using large cell culture flasks (Nunc; 850 ml). IMR32 medium was supplemented with 0.1 volumes of fetal calf serum and 3.5 g/1 glucose. TE671 cells were grown in 0.05 volumes of fetal calf serum supplemented medium in the presence or absence of 2.5 μιηοΐ/ΐ dexamethasone (Sigma). Both lines were grown in confluent monolayers and removed mechanically before use.
Gel filtration of α-bungarotoxin binding proteins IMR32 and TE671 cells (5 χ ΙΟ 8 ) were solubilized with 10 g/1 Triton X100 (Sigma) in 10 mmol/1 sodium phosphate buffer (pH 7.2) for 1 h, by gently shaking, and ultracentrifuged at 4°C and 100 000 £ in a Kontron^ ultacentrifuge (Kontron TGA-65; rotortype: 50 Ti) for 40 min. The supernatant was filtered through glass wool and the resulting solubilized cell line extracts were incubated with an excess (0.185 MBq) of [ 125 I]ctbungarotoxin (Amersham & Buchler; IM-109) for approximately 16 h at 4 °C. Unbound ligand was removed by column gel filtration, using a 30 χ 1.8 cm Sephadex G50 filled column (Pharmacia). Radioactivity of various fractions was measured using a gamma counter (Minaxi-gamma; Packard). Molecular masses of [ 12S I]a-bungarotoxin binding proteins in the cell lysates were determined by gel filtration, using defined standard proteins (Sigma).
Affinity chromatography of α-bungarotoxin binding proteins
Lysates of IMR32 and TE671 cells (5 χ ΙΟ 8 ) were prepared as described above and incubated overnight with a-bungarotoxincoupled (21 Gel) Sepharose 4B (Pharmacia). Coupling was achieved as described by the manufacturer. Thereafter the gel was washed intensively with 1 mol/1 sodium chloride in 10 mmol/1 sodium phosphate containing 10 g/1 Triton XI00. The α-bungarotoxin binding proteins were then eluted with 20 g/1 sodium dodecylsulphate (SDS), concentrated, and analysed under non-reducing conditions by SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
SDS-PAGE of α-bungarotoxin binding proteins
Affinity purified α-bungarotoxin binding proteins were reduced at 37 °C with 30 ml/l mercapt ethanol, then applied to a 10% or 12.5-7.5% SDS-PAGE according to Laemmli (11) . The proteins were separated at a constant current of 50 mA for 2.5 h in a vertical gel electrophoresis system (VA 150; Desaga). For the determination of protein size, high molecular mass standard proteins (Gibco-BRL; Amersham & Buchler) were run in parallel. Proteins were stained with 2 g/1 Coomassie Blue (Merck).
Cross-reaction of α-bungarotoxin binding proteins with myasthenia gravis patient sera Labelled α-bungarotoxin binding components were obtained from crude extracts of TE671 and IMR32 cells by gel filtration as described above. Pooled peak fractions were used in an immunoprecipitation assay with human myasthenia gravis sera.
[ 125 I]a-Bungarotoxin-labelled complexes from TE671 or IMR32 cells were incubated for 6 h at 4 °C with 5 μΐ of myasthenia gravis patient sera. Immunoprecipitation was done with an equivalent volume of goat anti-human IgG's (Lawrence Laboratories, Australia). The precipitates were pelleted by centrifugation at 11000 g in an Eppendorf centrifuge, then washed twice with 10 g/l Trition X-100 containing 10 mmol/1 sodium phosphate buffer. The radioactivity was measured in a gamma counter (Minaxi-gamma; Packard).
Purification of acetylcholine receptor from TE671 cells
For affinity chromatography of acetylcholine receptor from TE671 and human muscle ecus, α-najatoxin was prepared from crude snake toxin as described by Karlson & Widlund (12) . Acetylcholine receptor were purified according to the method described by Katies & Kalden (13) . Briefly, the α-najatoxin was coupled to cyanogen bromide-activated sepharose (2 g/1 gel; Pharmacia). Thereafter, cell extracts from TE671 cells or human muscle tissue were loaded on the column. After removing unspecifically bound proteins with 1 mol/1 sodium chloride, acetylcholine receptors were eluted with 1 mol/1 carbamylcholine. The purified acetylcholine receptors were labelled with [ 125 I]abungarotoxin in excess and used as antigens in a radioimmunoassay (RIA) as previously described (13, 14) .
Concentrations of anti-acetylcholine receptor autoantibodies given in nmol/1 were determined from the pelleted radioactivity and are equally expressed as the number fo α-bungarotoxin binding sites precipitated per litre of serum. For the calibration of the RIA a control standard serum was used as previously described (15) . For inhibition experiments, 5 χ ΙΟ 4 cells of IMR32 or TE671 cells were preincubated with the indicated concentrations of α-bungarotoxin (Serva). Acetylcholine receptors were stimulated with 10 mmol/1 of the agonist carbamylcholine (Sigma) in phosphate-buffered saline. After 30 min, cells were pelleted and washed twice with ice-cold phosphate-buffered saline. The reaction was stopped by adding 0.1 ml of 1.5 mol/1 perchloric acid (16) . After neutralisation the probes were centrifuged at 5000 g. The supernatants were collected, stored up to 4 weeks at -70 °C or immediately tested for cAMP. cAMP was measured in duplicates (10 μΐ) according the method of Oilman (17) When α-bungarotoxin binding proteins from TE671 and IMR32 cells were affinity purified using α-bungarotoxin Sepharose 4B, then analysed with SDS-PAGE ( fig. 2a and 2b) , it was shown that the abungarotoxin binding protein of TE671 cells consisted of subunits of Μ τ 44000, 59000, 54000 and 68000, which corresponds with the known characteristics of the α-, β-, γ-and δ-subunits of the human muscle nicotinic acetylcholine receptor (22) . In contrast, SDS-PAGE of the α-bungarotoxin binding protein of IMR32 cells showed one strong subunit band at M r 50 000 and some weaker bands with higher and lower molecular masses. At present it is not clear whether these bands represent various subunits or degradation products.
Reactivity of α-bungarotoxin binding proteins with myasthenia gravis patient serum antibodies Constant amounts of radiolabelled α-bungarotoxin binding proteins from IMR32 and from TE671 (20000 counts per minute) were incubated with undiluted serum from myasthenia gravis patients. It was demonstrated that almost all sera from patients with myasthenia gravis precipitated high amounts of radioactively labelled α-bungarotoxin binding proteins from TE671, but not from IMR32 (tab. 1). This indicates that α-bungarotoxin binding proteins from TE671 cells immunologically represent acetylcholine receptor. This is not the case, however, for α-bungarotoxin binding proteins expressed on IMR32 cells. Reactivity of myasthenia gravis patient serum autoantibodies with affinity chromatography-purified acetylcholine receptor from TE671 cells and human muscle tissue When affinity chromatography-purified acetylcholine receptor from TE671 cells and muscle tissue were tested in a fluid phase radioimmunoassay as described (14) (15) , there was a very good correlation (r = 0.96) with the autoantibody concentrations (nmol/1) in 66 sera of patients with myasthenia gravis (fig. 3 ). This is further evidence for the expression of an imrnunologically identical acetylcholine receptor on TE671 cells, compared with that on human muscle tissue.
No such correlation could be demonstrated when abungarotoxin binding proteins from IMR32 cells were used as substrate for this assay.
Changes in intracellular cAMP concentrations after stimulation with carbamylcholine
To test whether the α-bungarotoxin binding proteins on TE671 and IMR32 cells represent functional acetylcholine receptor, different intracellular second messenger mechanisms in carbamylcholine stimulated cells were investigated. Two different assays were used to test signal transduction in TE671 and IMR32 cells: 1) changes in intracellular cAMP concentrations, and 2) the increase in intracellular Ca 24 
" concentrations
No significant increase of cAMP in either of the tested cells were observed after stimulation with carbamylcholine. However, when TE671 cells were preincubated for l h with 100 μιηοΐ/ΐ forskolin, which is known to be a potent adenylate cyclase activator, cAMP concentrations increased to approximately 1 30% compared with unstimulated cells. This increase was blocked by oc-bungarotoxin ( fig. 4a ) and was enhanced when TE671 cells were grown in dexamethasone ( fig. 4b) . In contrast, no increase of cAMP in IMR32 cells was obtained after stimulation with carbamylcholine, no matter what culture conditions were used (with or without forskolin or dexamethasone; data not shown).
These observations indicate that carbamylcholine treatment stimulated an increase of cAMP in TE671 cells under certain conditions. It is likely that this effect is mediated through a human acetylcholine receptor expressed on TE671 cells. In contrast, no such effect was observed with IMR32 cells. The increasing effect of dexamethasone treatment in TE671 cells is consistent with experiments by Luther & Lindstrom who described an increase of acetylcholine receptor ]i to about 50% ( fig. 5a-d) . Interestingly, the serum of a patient with Lambert-Eaton syndrome was also able to suppress the increase in [Ca 2+ ]j (fig. 5e ). The fact that this patient's serum was negative in conventional radioimmunoassay for the presence for anti-acetylcholine receptor antibodies is consistent with reports by Sher & dementi (24) suggesting that Lambert-Eaton syndrome patient sera contain autoantibodies reacting with calcium channels. No inhibition of the carbamylcholine-induced increase in [Ca 2+ ]i in TCE671 cells was found when sera from healthy donors (n = 5) were used ( fig. 5f) . None of the other tested sera from myasthenia gravis patients (n = 7) showed any inhibition of the calcium response. There was no correlation between acetylcholine receptor antibody titres in myasthenia gravis patient sera and their correlation to inhibit the calcium response. This might be due to the fact that autoantibodies against the acetylcholine receptor are directed against different epitopes of the receptor complex (25, 26) and might therefore differ in their functional capabilities. Tab 
Discussion
The binding of the snake venom α-bungarotoxin is a characteristic property of the human acetylcholine receptor. In this paper we describe two human tumour cell lines that were previously demonstrated to bind α-bungarotoxin in vitro. One of these cell lines, TE671, which was originally described as a medulloblastoma cell line (7), is derived from a rhabdomyosarcoma (8) . The second cell line investigated, IMR32, originates from a human neuroblastoma (10) .
Applying gel filtration techniques, the α-bungarotoxin binding protein from TE671 cells exhibited a considerably higher molecular mass than the oc-bungarotoxin protein isolated from IMR32 cells. When a-bungarotoxin binding proteins from the two cell lines were analysed by SDS-PAGE, the molecular mass and subunit composition of the α-bungarotoxin binding structure from TE671 cells showed a similar pattern to that known for the nicotinic acetylcholine receptor isolated from human muscle (21) . The acetylcholine receptor purified from TE671 consists of subunits of Μ τ 44000, 50000, 54000 and 68000, which is consistent with the known characteristics of the α-, β-, γ-and δ-subunits of the human muscle nicotinic acetylcholine receptor. In contrast, the α-bungarotoxin binding protein from IMR32 cells showed a distinct pattern of one strong band at M T 50 000 accompanied by weaker bands with higher and lower molecular masses. At present it is not clear if these differences in the protein pattern are due to the presence of different receptor subunits or degradation products.
When the immunological cross-reactivity was tested using sera from myasthenia gravis patients, a high cross-reactivity was found between a-bungarotoxin binding proteins from TE671 cells and human muscle acetylcholine receptor, whereas no cross-reactivity was found when α-bungarotoxin binding proteins from IMR32 cells were used as antigen. These data suggest that the α-bungarotoxin binding protein expressed on TE671 cells represents biochemically and imrnunologically intact human nicotinic acetylcholine receptors. This is apparently not true for the α-bungarotoxin binding protein from IMR32 cells.
In additional studies, second messenger mechanisms in TE671 cells and IMR 32 cells were tested after the cells had been stimulated with the acetylcholine receptor agonist c rbamylcholine. In TE671 cells, an increase in cAMP concentrations was induced by c rbamylcholine, but only when cells were pretreated with forskolin. This effect was inhibited by the addition of various concentrations of α-bungarotoxin. In addition, there was a pronounced increase in intracellular cAMP concentrations in cells grown in media supplemented with dexamethasone, which is known to induce and increase the acetylcholine receptor expression (22, 23) . No increase in cAMP was seen in identically treated IMR32 cells. (27) . The stimulation of acetylcholine receptor leads to the action of protein kinase and a cAMP-dependent protein kinase, followed by a desensitization of receptors (28, 29) . Therefore, the agonist-induced decrease in channel currents of muscle nicotinic acetylcholine receptor may be related to intracellular Ca 2+ concentrations (30) . All these findings support the role of Ca 2+ and cAMP in the muscle activation process. In one part of our experiments we measured an increase in intracellular Ca In addition, Bencheriff & Lukas described the existence of muscarinic acetylcholine receptors on the TE671 cell line (31) . However, it is unlikely that the [Ca 2+ ]i increase in TE671 cells is mediated through muscarinic acetylcholine receptor, because this should not be blocked by α-bungarotoxin. Many questions remain concerning signal transduction pathways in malignant cell lines. For example Morris & NewsomDavis described two α-subunit isoforms of the acetylcholine receptor in TE671 cells (32) . A differential expression of these isoforms therefore may lead to an altered intracellular signal transduction pathway.
To investigate the role of acetylcholine receptor-function-inhibiting autoantibodies, we preincubated TE671 cells with myasthenia gravis patient sera prior to stimulation with c rbamylcholine. Four out of 11 myasthenia gravis patients sera had an inhibiting effect on the maximal amplitude and duration of [Ca 2 "*"]j increase in TE671 cells. However, no correlation could be obtained with acetylcholine receptor serum antibody titres. This finding could be explained by the well documented effect that acetylcholine receptor directed antibodies in myasthenia gravis patients sera are characterized by a considerable heterogeneity in terms of their reactivity to different epitopes on various subunits of the acetylcholine receptor. This observation is also in agreement with data published by Lang & Newsom-Davis (33), who demonstrate that acetylcholine receptor antibodies inhibiting Na"*" influx in stimulated TE671 cells were present in only about 30% of myasthenia gravis patients' sera (34) . Interestingly, the serum from one patient with a Lamberi-Eaton symdrome also showed an inhibitory effect on the intracellular Ca 2+ response in carbamylcholine-stimulated TE671 cells. This patient serum did not contain any detectable anti-acetylcholine receptor antibodies, which is in concordance with a report by Sher & dementi (24) who described specific antibodies against Ca 2+ -channels in sera of Lambert-?Eaton patients, with the functional capacity to cause myasthenia gravis-like symptoms.
In summary, our data suggest that the oc-bungarotoxin-binding proteins in TE671 cells represent immunologically and functionally intact human nicotinic acetylcholine receptors. Therefore, TE671 cells are not only useful for the isolation of acetylcholine receptors, but also for functional studies on the effects of various types of anti-acetylcholine receptor antibodies in myasthenia gravis patient sera. It remains to be ascertained whether the observation that about one third of myasthenia gravis patient sera were capable of modulating second messenger pathways in the TE671 cell line is of clinical relevance.
